Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €4.13 EUR
Change Today -0.021 / -0.51%
Volume 654.3K
EVT On Other Exchanges
As of 12:43 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/15 - €4.22
52 Week Low
10/16/14 - €2.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG provides drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as anti-infectives, target identification and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism, and excretion) profiling, proteomics, cell and protein production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; Somatoprim that is in Phase II clinical trials for the treatment of Acromegaly; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, and EVT770 for diabetes type 2/1; and discovery stage products comprise various products for inflammation, diabetes type 2/1, kidney disease, oncology, Alzheimer’s disease, and CNS/MS. The company has alliances and partnerships with AstraZeneca AB, Bayer Pharma AG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., Jain Foundation Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Novartis AG, F. Hoffmann-La Roche AG, Shire plc, and UCB Pharma. It also has strategic collaborations with Apeiron Biologics AG, Fraunhofer Institute for Molecular Biology and Applied Ecology, and Sanofi; and collaboration with Convergence Pharmaceuticals Holdings Ltd., Debiopharm Group, Eternygen GmbH, Medicines for Malaria Venture, and Second Genome, Inc. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

956 Employees
Last Reported Date: 08/12/15
Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €459.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €323.0K
Chief Operating Officer and Member of Managem...
Total Annual Compensation: €361.0K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €361.0K
Compensation as of Fiscal Year 2014.

evotec ag (EVT) Key Developments

Evotec Enters Multi-Year Contract to Manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center

Evotec AG announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute (NCI), Department of Health and Human Services. Under the terms of the agreement, Evotec will provide compound management services to the NCI Chemical Biology Consortium (CBC)for a period of five years with a total estimated value of up to EUR 4.5 million. The NCI Chemical Biology Consortium contract will continue to provide to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of primarily academic and non-profit institutions.

Evotec AG Increases Revenue Guidance for 2015

Evotec AG announced that it increases its financial guidance for the current year. The company now expects group revenues excluding milestones, upfronts and licences to increase by approximately 45% (previously: more than 35%) compared to last year (2014: EUR 73.4 million) mainly as a result of the company’s strong business performance of the company’s Execute, accelerated growth in the company’s Innovate business and a positive outlook for the remainder of the year.

Evotec AG Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 01:00 PM

Evotec AG Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 01:00 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Werner Lanthaler, Chief Executive Officer and Member of Management Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €4.13 EUR -0.021

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.89 USD -0.09
CTI BioPharma Corp $1.62 USD -0.01
Cytokinetics Inc $6.89 USD -0.14
GlaxoSmithKline SAE £10.30 EGP 0.00
Infinity Pharmaceuticals Inc $7.74 USD -0.053
View Industry Companies

Industry Analysis


Industry Average

Valuation EVT Industry Range
Price/Earnings 50.4x
Price/Sales 5.3x
Price/Book 3.1x
Price/Cash Flow 41.2x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at